R1 Therapeutics Launches with $78 Million Funding Round, Secures Kidney ...

R1 Therapeutics launches with $77.5M Series A to advance first-in-class kidney disease treatment AP306 - Tech Startups

For decades, hyperphosphatemia in chronic kidney disease has been treated with therapies that often fall short. Now, a new biotech startup, R1 Therapeutics, is aiming to change that with fresh funding and a different approach. The company has launched from […] The post R1 Therapeutics launches with $77.5M Series A to advance first-in-class kidney disease treatment AP306 first appeared on Tech Startups.

R1 Therapeutics launches with $78 million funding round, secures kidney ...

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia....

R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment

Financing and global licensing deal to accelerate phase 2b development of AP306

New renal disease biotech R1 Therapeutics nabs $77.5M for Phase 2b

A fresh renal disease biotech expects to be on the market with a new hyperphosphatemia medicine for dialysis patients by the end of this decade, and it might still be a private company when it ...